A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : VEN / venetoclax

[Related PubMed/MEDLINE]
Total Number of Papers: 9
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   VEN  (>> Co-occurring Abbreviation)
Long Form:   venetoclax
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model. AML, AZA, CDA, CDX, CDZ, DEC, DNMTis, i.v, MDS, PDX, s.c
2020 Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. AML, HMAs, IC, OS
2020 Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. AML, Aza, MDS
2020 Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. AML, FLT3, FLT3m, HMA, LFS
2020 Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience. AML, HMAs, LDAC, ORR, OS
2019 A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. CI, CLL, CR, HRs, ORRs, OS, PFS, R/R
2019 Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. AML, CR
2018 Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. AML, BPDCN, CR, HMA, LDAC, MDS, MLFS, R/R
2017 Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. CLL, CpG ODN, IBR, MCL